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Objectives: To compare both economic and clinical impact of alternative cer-
vical cancer (CC) screening strategies for women 25-65 years old using different 
algorithms with primary screening methods including cytology alone or hrHPV 
test and genotyping. MethOds: Screening and diagnosis of CC were modeled by 
a decision tree while the natural history of the disease was simulated by a Markov 
model using published available data. The compared strategies were: 1) trienni-
ally hrHPV testing with 16/18 genotyping and reflex cytology 2) triennially HPV 
testing with reflex genotyping and reflex cytology and 3) annually cytology alone. 
Clinical inputs were derived from the HERMES local trial. Unit costs for the resources 
used were obtained from the official price lists while the HPV test cost was based 
on the private’s sector prices. In the absence of relevant data, the cost of treat-
ing cervical intraepithelial neoplasia (CIN2+) and invasive CC was based on the 
respective Spanish costs which were converted to 2014 Greek values using the rel-
evant Consumer Price Index and Purchasing Power Parity exchange rate. Results: 
Strategy 1 was proved to be the dominant option as it was estimated to be less costly 
and more effective. In more detail, cytology alone detected 58% and 52% of CC and 
CIN2+ cases, respectively while strategies 1 and 2 managed to detect 94% and 85% 
of CC and CIN2+cases,respectively. In terms, of CCs missed, strategy 3 appears to 
miss 24 incidents annually in contrast to 18 of strategies 1 and 2. The annual cost 
of strategy 1 was estimated at € 14,568,412 compared to the cost of strategy 2 and 3 
which was estimated at € 38,109,522 and € 18,209,511, respectively. cOnclusiOns: 
The adoption of hrHPV test with 16/18 genotyping as a primary screening method 
can generate significant savings to the Greek health care system and in parallel 
optimize health outcomes.
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Objectives: Our objective was to study the economic impact of the four main 
endovascular treatment strategies for femoropopliteal arterial disease on payers 
in the German healthcare system, using up-to-date clinical evidence and current 
reimbursement amounts. MethOds: We estimated latest clinical performance of 
percutaneous transluminal angioplasty (PTA), bare metal stents (BMS), drug-coated 
balloons (DCB), and drug-eluting stents (DES) by performing a systematic search for 
studies published through 2014 that reported target lesion revascularization (TLR) 
as an endpoint. 24-month TLR rates were estimated for each treatment weighted 
by sample size. We updated a previously published decision-analytic Markov model 
to assess budget impact to payers of the four index procedure strategies using 
2015 reimbursement rates for Germany and considering up to one reinterven-
tion. Results: Twenty-nine studies were included. Pooled 24-month probabilities 
of TLR were 16.5%, 19.4%, 26.9%, and 39.6% for DCB, DES, BMS, and PTA, respectively. 
Over 24 months, DES had the lowest budget impact to payers of € 3,799, closely fol-
lowed by DCB (€ 3,913). The corresponding amounts for BMS and PTA were € 4,189 
and € 4,451, respectively. Comparing the most effective (DCB) to the least effective 
therapy (PTA), we found a number needed to treat (NNT) of 4.34. This suggests that 
for every four patients treated with DCB as opposed to PTA, one TLR could be avoided 
over 24 months, at overall cost savings to the healthcare system. cOnclusiOns: 
Latest clinical evidence suggests that drug-coated balloons provide the most favora-
ble clinical outcome among the considered endovascular treatments for femoro-
popliteal artery disease. Our updated economic analysis finds DES and DCB to also 
be associated with lowest cost to payers in the German healthcare system, closely 
followed by drug-eluting stents. These results, based on larger evidence base, con-
firm earlier findings.
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Objectives: IBS is considered a diagnosis of exclusion based on several labo-
ratory and diagnostics procedures to exclude other organic conditions. A novel 
IBS diagnostic blood panel has been developed which tests for the presence of 
two biomarkers associated with IBS-D. This analysis estimates the cost impact 
to the Italian healthcare system by introducing this test into the diagnostic 
pathway. MethOds: A budget impact model was based on a cost-minimization 
decision model developed to compare the costs associated with two possible 
diagnostic pathways: (1) diagnostic pathway with a novel IBS diagnostic blood 
panel and (2) exclusionary diagnostic pathway and applied to the Italian popula-
tion 18-65yrs old. Model structure was based on current literature and guidance 
from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnostic 
procedures and visit costs were included in Euros and weighted by utilization 
rates provided by practicing gastroenterologists in Italy. Indirect cost estimate 
was based on the literature and only included time off work, adjusted for per 
capita income in Italy. Results: Colonoscopy, ultrasound and SBFT were the most 
common diagnostic (instrumental) procedures reported with estimated utilization 
rates of 50%, 90% and 35%, respectively. Corresponding charges were € 312.50, € 70 
and € 300, respectively. Estimated total base case charges for the IBS diagnostic 
panel pathway (assumes 75% of test positive patients receive IBS-D treatment) 
vs the exclusionary pathway were € 1,351 vs € 1,425, respectively. If clinicians use 
the test 50% of the time for the 50% of the estimated 447,275 people who might 
have IBS-D who seek treatment, net savings to the Italian healthcare system is 
€ 27,581,982. Cost neutrality occurs if 49% of the “test positive” patients seek IBS 
standard care. Related costs were calculated according to Greek NHS official prices. 
The analysis was undertaken from a Greek third-party payer perspective. Results: 
According to the model, the reduction in expenditures related to diagnosis and prog-
nosis/monitoring with NT-proBNP use were estimated at € 6.8 and € 3.2 million/year 
respectively. The projected net savings, considering the cost of NT-proBNP implemen-
tation (€ 718,000), were calculated at € 9.3 million. NT-proBNP testing also generated 
reduced use of health care resources, by preventing 1,890 initial hospitalizations/year, 
leading to 10,235 fewer hospitalization days in general ward and 3,232 in intensive 
care unit, and avoiding 491 hospital readmissions/year. cOnclusiOns: The overall 
reductions in hospitalizations and length of stay, achieved by early diagnosis and 
prognosis of HF with the implementation of NT-proBNP, could generate cost-savings 
and increase hospitals’ efficiency and productivity.
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Objectives: Existing guidelines recommend determination of RAS mutation sta-
tus in patients with metastatic colorectal cancer (mCRC) as anti-epidermal growth 
factor receptor (anti-EGFR) therapies are ineffective in tumors with RAS mutations. 
The cobas® KRAS Mutation Test (cobas test) detects twelve mutations in KRAS 
exon 2 and seven mutations in exon 3, whereas the therascreen KRAS RGQ PCR 
Kit (therascreen test) detects seven overlapping mutations in KRAS exon 2. We 
estimated the potential clinical and economic impact of using the cobas test versus 
the therascreen test in all mCRC patients in Denmark. MethOds: A budget impact 
model was developed from the Danish healthcare perspective. Model inputs were 
obtained/estimated from the literature (e.g. 1,260 annual mCRC cases were esti-
mated). Treatment patterns were from Roche data on file. Sensitivity and specificity 
were assumed to be the same as positive percent agreement and negative percent 
agreement comparing to Sanger sequencing, which were 96.9% and 88.7% for cobas, 
94.2% and 87.5% for therascreen. Drug and treatment-related costs were calcu-
lated from the national pharmaceutical procurement service (Amgros) and Danish 
national tariffs, respectively. The model calculated the average treatment cost for 
mCRC patients over 5 years, using median time on treatment and median overall 
survival. Costs were presented in 2015 Euros (1 Euro = 7.46021DKK). Results: Using 
the cobas test resulted in a reduction of 63 patient-months lost due to inappropri-
ate care (avoiding anti-EGFR therapies in mutant patients) and an improvement in 
median overall survival. Using cobas KRAS testing reduced the costs of inappropri-
ate care by € 991K and decreased monthly cost per patient by € 3, while having a 
minor increase (€ 105K, 0.2%) in healthcare costs. cOnclusiOns: Using the cobas 
test with better sensitivity and broader mutation coverage of KRAS was associated 
with a neutral budget impact and may improve patient outcomes by reducing the 
likelihood of receiving inappropriate care in mCRC patients.
PMD29
IntroDuctIon oF an organIzatIonal MoDEl oF tElEMEDIcInE In 
ManagEMEnt oF oral antIcoagulant thEraPy: a BuDgEt IMPact 
analysIs FroM ItalIan PayEr PErsPEctIvE
Dionisi M1, Santomauro M2, Santagada V2, Santomauro MA2, Garofalo G2, Vosa C2, Paolini 
D1
1Roche Diagnostics S.p.A., Monza, Italy, 2Federico II University of Naples, Napoli, Italy
Objectives: Oral Anticoagulant Therapy (OAT) with antivitamin K antagonists for 
prevention of thromboembolic and vascular events requires a frequent monitoring 
of prothrombin time and a dose adjustment to maintain the intensity of anticoagula-
tion within a safe and effective range. The objective of the study was to quantify the 
budget impact after the introduction of the decentralized monitoring model for OAT 
patients. This model creates a link between specialized hospitals and pharmacies 
in the territory using Point-of-Care coagulometer CoaguChek and the telemedicine 
system TaoWeb, guaranteeing fewer adverse events thanks to increased accessibility 
to the service, compared to the centralized monitoring model and non-specialized 
monitoring model, and an elevated standard of quality. MethOds: A comparative 
analysis was carried out on three patient management models following the prospec-
tive of NHS with a time horizon of five years, taking the following into account: phar-
maceutical treatments, patient monitoring and adverse events. The rate of adverse 
events was estimated from scientific literature and the consumption of resources 
was quantified taking into consideration the DRG tariffs and the outpatient national 
tariff list. Results: The adoption of the decentralized monitoring model compared 
to the centralized and non-specialized model leads to an annual saving of € 236.45 and 
€ 525.15, respectively. Considering a target population of 491,093 patients requiring 
OAT and the monitoring model distribution among patients is 1.7% with the decen-
tralized model, 86.4% with the centralized model and 11.9% with the non-specialized 
model. Assuming an incremental adoption rate of 6% per year of decentralized moni-
toring, the model predicted an annual cost saving of over € 43.3 million by its fifth 
year. cOnclusiOns: Despite initial higher investments for Point-of-Care coagulom-
eter and the telemedicine technology, the decentralized monitoring model for OAT 
patients allows a budgetary saving compared to centralized monitoring model and 
non-specialized monitoring model with a potential increase of patient quality of life.
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